IDbyDNA

13 articles about IDbyDNA

• IDbyDNA Awarded Additional DARPA Funding to Continue Development of DIGET Program to Support Detection of Infectious Disease for US Military Applications

  4/7/2022

  IDbyDNA, the company revolutionizing the use of Precision Metagenomics, has been awarded a second year of funding by MRIGlobal to continue participation in the "Detect It with Gene Editing Technologies" program for the United States Defense Advanced Research Projects Agency.

• 

  BioSpace Movers & Shakers, May 7

  5/7/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  IDbyDNA’s Metagenomics Suite Future-Proofs Labs for Coming Pathogen Crises

  4/6/2021

  IDbyDNA’s metagenomic approach to viral strain identification combines very sensitive detection with next-gen sequencing to identify emerging and mutant viruses much sooner than either genomic or surveillance methods alone.
• 

  Biopharma Update on the Novel Coronavirus: July 15

  7/15/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.

• IDbyDNA and Illumina Partner to Deliver NGS Infectious Disease Solutions

  3/17/2020

  Partnership Aims to Accelerate NGS Adoption for Clinical Infectious Disease Testing by Combining Comprehensive Sequencing Workflows with Turn-key Clinical Informatics SAN FRANCISCO--( BUSINESS WIRE )-- IDbyDNA Inc., a metagenomics technology company setting a standard for detection, identification and interpretation of microorganisms and their role in human health, today announced a global strategic partnership with Illumina, Inc. (Nasdaq: ILM

• Novel Wuhan Coronavirus Detectable with IDbyDNA Explify Respiratory Test

  1/28/2020

  IDbyDNA, Inc., a metagenomics technology company setting the standard for detection, identification and interpretation of microorganisms and their role in human health, announced that its currently available Explify Respiratory test can detect 2019-nCoV in addition to over 900 other viral, bacterial, fungal and parasitic pathogens.

• IDbyDNA and Rady Children’s Institute for Genomic Medicine Partner on Clinical Trial for the Identification of Pediatric Central Nervous System Infections

  10/3/2018

  The Rady Children’s Institute for Genomic Medicine (RCIGM) and IDbyDNA, a metagenomics technology company translating microbial genomics into actionable information for healthcare providers, have launched a clinical trial to improve diagnostics for pediatric central nervous system (CNS) infections.

• IDbyDNA Announces a Strategic Partnership with the Fleury Group Medical and Health Organization to Utilize the Explify® Platform Across South America

  9/19/2018

  IDbyDNA to license the Explify technology platform to Fleury, to perform high quality clinical metagenomic testing within their markets

• Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test for Pseudomonas Aeruginosa Infection

  1/3/2018

  Once LBx-PA01 reaches the market, the test will ensure that the medication will be given to patients with the greatest opportunity to benefit from it, improving patient outcomes and reducing the overall cost of treatment.

• IDbyDNA And ARUP Laboratories Introduce Explify Respiratory: Breakthrough Technology To Diagnose Pneumonia Caused By Previously Undetected Pathogens

  9/19/2017

• IDbyDNA And ARUP Laboratories Announce Partnership To Develop And Commercialize Novel Infectious Disease Testing Using Metagenomics

  7/31/2017

• The New England Journal of Medicine Publishes Study On Zika Genomic Sequence Identification By IDbyDNA

  9/29/2016

• IDbyDNA Raises $9 Million In Series A To Bring Precision Medicine To Infectious Diseases

  9/8/2016